Prudential Financial’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Prudential Financial’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-34,645	Closed	-$235K	–	2786
2022 Q1	$235K	Buy	34,645 +14,300	+70%	+$102K	﹤0.01%	2473
2021 Q4	$170K	Buy	+20,345	New	+$168K	﹤0.01%	2563
2020 Q4	–	Sell	-43,850	Closed	-$358K	–	2519
2020 Q3	$358K	Sell	43,850 -1,490	-3%	-$9.24K	﹤0.01%	2089
2020 Q2	$312K	Sell	45,340 -25,293	-36%	-$136K	﹤0.01%	2103
2020 Q1	$335K	Sell	70,633 -28,206	-29%	-$162K	﹤0.01%	2034
2019 Q4	$863K	Sell	98,839 -33,462	-25%	-$181K	﹤0.01%	1913
2019 Q3	$440K	Sell	132,301 -117,933	-47%	-$472K	﹤0.01%	2087
2019 Q2	$1.24M	Buy	250,234 +42,011	+20%	+$223K	﹤0.01%	1804
2019 Q1	$1.29M	Buy	208,223 +170,268	+449%	+$823K	﹤0.01%	1787
2018 Q4	$127K	Buy	+37,955	New	+$177K	﹤0.01%	2287
2017 Q3	–	Sell	-68,280	Closed	-$958K	–	2385
2017 Q2	$958K	Buy	+68,280	New	+$1.46M	﹤0.01%	1849

Other funds holding JNCE

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

Prudential Financial's JNCE Position: Q2 2022 in Review

Prudential Financial sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2022, closing a stake of 34,645 shares — an estimated $235K sold.

Prudential Financial first reported a position in JNCE in Q2 2017 and held it in 11 quarters. The position peaked at $1.29M in Q1 2019. 102 funds tracked by Wall St. Rank hold JNCE as of Q2 2022.

Prudential Financial reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Prudential Financial sold 34,645 Jounce Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $235K.
Prudential Financial first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2017 and held it in 11 quarters.
Prudential Financial's Jounce Therapeutics, Inc. Common Stock position peaked at $1.29M in Q1 2019.
102 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Prudential Financial's 13F filing for Q2 2022, filed 15 Aug 2022.